Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Leeward Investments LLC MA

Leeward Investments LLC MA trimmed its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 0.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 404,728 shares of the company’s stock after selling 1,365 shares during the period. Prestige Consumer Healthcare comprises 1.4% of Leeward Investments LLC MA’s investment portfolio, making the stock its 13th largest position. Leeward Investments LLC MA owned 0.82% of Prestige Consumer Healthcare worth $29,181,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Prestige Consumer Healthcare by 6.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,579 shares of the company’s stock worth $1,929,000 after purchasing an additional 1,543 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Prestige Consumer Healthcare by 143.4% during the first quarter. BNP Paribas Financial Markets now owns 51,246 shares of the company’s stock worth $3,718,000 after purchasing an additional 30,191 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Prestige Consumer Healthcare during the first quarter worth $428,000. Texas Permanent School Fund Corp lifted its position in shares of Prestige Consumer Healthcare by 1.4% during the first quarter. Texas Permanent School Fund Corp now owns 43,452 shares of the company’s stock worth $3,153,000 after purchasing an additional 588 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Prestige Consumer Healthcare during the first quarter worth $218,000. 99.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PBH has been the topic of a number of recent research reports. Jefferies Financial Group reissued a “hold” rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson lifted their price target on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and an average target price of $94.20.

Prestige Consumer Healthcare Stock Up 3.6 %

PBH stock opened at $77.44 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.23 and a quick ratio of 1.90. Prestige Consumer Healthcare Inc. has a 1-year low of $56.61 and a 1-year high of $79.25. The firm has a fifty day moving average price of $72.31 and a two-hundred day moving average price of $69.71. The firm has a market cap of $3.84 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 2.08 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.04. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The firm had revenue of $267.10 million during the quarter, compared to analyst estimates of $260.54 million. During the same quarter in the previous year, the firm earned $1.06 earnings per share. The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. Research analysts predict that Prestige Consumer Healthcare Inc. will post 4.43 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.